Scienza e Tecnologia
Daewoong, Q1 is just early stage of better performance
Nabota's sales reached 15.4 billion won from 15.1 billion won Q1, 2020. Not only did domestic sales increase, but ITC's agreement on February 19 resolved uncertainties, resulted in surged U.S. sales, marking the historical high performance in March. Turkey and Chile , which recently acquired product licenses, are also planning to launch Nabota in Q3.
HanAll Biopharma, a major subsidiary, recorded 27.8 billion won this year from 22.1 billion won in sales in the same period last year, and its operating profit increased from 3 billion won to 5.4 billion won during the same period. Upfronts for new drug candidates, such as HL036(for dry eyes) and HL161(for autoimmune diseases) contributed to make better performance.
"We have been showing sluggish performance by many non business factors, but our performance defintely begun to improve from Q1. In particular, Nabota's scalability in U.S. is just opening and it is expected to stand out in Europe , China and other markets." said from an insider. "Foistar Tab and DWRX2003(Niclosamide) for COVID19 treatmenmt and new drugs such as Fexuprazan and Enavogliflozin, are also considered to have great market potential" he said.
Meanwhile, Daewoong Co., a holding company of Daewoong Pharma., also announced its Q1 performance(based on consolidation). Its sales grew 6.2 percent year-on-year to 348.5 billion won and operating profit rose 78.7 percent to 44.3 billion won .
Daewoong Pharma. is a global healthcare corporation founded in 1945 with the belief to 'create good medicine to protect the health of the people and create a healthy society.' Major business areas are hospital prescription drug (ETC) sector, over-the-counter medicine (OTC) sector, exportation of finished products and raw material medicine sector, and consignment production sector. Daewoong continues to invest more than 10% of its sales in R&D every year, focusing on developing gastrointestinal(GI), endocrine, orphan and stemcell based therapeutics.
Daewoong IR team (t_797rx@daewoong.co.kr) or
HanAll IR team (ir@hanall.co.kr )